This review uncovers the efficacy of non-selective beta-blockers in managing portal hypertension, suggesting optimizations for treatment strategies.
Liver cirrhosis is the end stage of various chronic liver diseases, which is mainly divided into compensated stage and decompensated stage. Portal hypertension (PH) is a key factor leading to the progression from compensated to decompensated liver cirrhosis. Non‐selective beta‐blockers (NSBBs), as the cornerstone drugs for reducing portal vein pressure, have been widely used in the prevention and management of liver cirrhosis and PH‐related complications in recent years. This review summarizes the mechanisms, clinical efficacy, and controversies of NSBBs in the prevention of variceal bleeding, the management of ascites, and the prophylaxis of hepatocellular carcinoma. Further efforts are needed to optimize the indications for NSBBs and develop individualized treatment strategies.
No takes yet. Share an insight, caveat, or question.
Bu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: